Sign up Australia
Proactive Investors - Run By Investors For Investors

Midatech Phama signs US co-promotion deal for cancer care product

NeutraSal is prescribed for Xerostomia, also known as dry mouth syndrome, which is a common side-effect of cancer treatment
word cancer under the looking glass
The company is broadening its portfolio, which brings with it synergies

Midatech Pharma Plc (LON:MTPH) said its US arm has signed a deal that gives it the exclusive right to promote a cancer care product in the US.

It has inked a co-promotion agreement with Bausch Health Companies to for NeutraSal to oncology customers in the US.

In exchange for its efforts, Midatech will receive a percentage of the net sales. The financial terms of the agreement are undisclosed. 

Common cancer side-effect

The product is prescribed for Xerostomia, also known as dry mouth syndrome, which is a common side-effect of cancer treatment.

"NeutraSal provides oncology professionals with an effective therapy for patients suffering from Xerostomia, which can be a painful and debilitating side effect of certain cancer therapies,” said David Benharris, president of Midatech’s US business. 

He pointed synergies will be derived by selling a broader range of oncology products. “The addition of NeutraSal to our portfolio appreciably enhances our offering of effective treatment options to provide continuity of care for patients suffering from the side effects of cancer therapies," he explained.

View full MTPH profile View Profile

Midatech Pharma Plc Timeline

Related Articles

Vial of pills
June 25 2018
Cosmos is a modern company, but the trade routes it relies on are ancient
Cancer cells
June 27 2018
The Nottingham-based privately-owned company has made an impressive fist of developing the OMIS (Opto-magnetic Imaging Spectroscopy) cancer detection system
picture of cannabis plants
March 24 2018
Control of the supply chain offers operational advantages and financial benefits.

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use